Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026
Vanda Pharmaceuticals Inc. announced the resignation of Timothy Williams from his role as Senior Vice President, General Counsel, and Secretary. His resignation is effective April 10, 2026, as he is leaving to pursue other opportunities. The company made this announcement on March 29, 2026.
Vanda Pharmaceuticals executive Timothy Williams to resign as general counsel
Vanda Pharmaceuticals announced that Timothy Williams, Senior Vice President, General Counsel, and Secretary, will resign on April 10, 2026, to pursue other endeavors. This leadership change occurs as Vanda Pharmaceuticals experiences strong stock momentum and recent FDA approval for a new drug, Bysanti, although it is also facing regulatory challenges for Hetlioz. Analysts note the company's solid balance sheet but also its cash burn as it aims for profitability this year.
Vanda Pharmaceuticals executive Timothy Williams to resign as general counsel
Vanda Pharmaceuticals announced that Timothy Williams, Senior Vice President, General Counsel, and Secretary, will resign on April 10, 2026, to pursue other opportunities. This leadership change occurs as Vanda has shown strong stock performance, with shares up 57% over the past year, and appears undervalued. The company recently received FDA approval for its drug Bysanti and is awaiting a public hearing for Hetlioz, while also managing a refusal from the European Medicines Agency for Hetlioz in certain indications.
Vanda Announces Resignation of Senior Legal Executive
Vanda Pharmaceuticals announced the resignation of Timothy Williams, its Senior Vice President, General Counsel, and Secretary, effective April 10, 2026. This departure marks a significant change in the company's executive legal leadership, potentially impacting its corporate governance and strategic matters. The company's stock currently has a Hold rating with a $7.00 price target from analysts, while TipRanks' AI Analyst Spark rates VNDA as Neutral due to weak financial performance despite strong technical momentum.
Vanda Pharmaceuticals executive Timothy Williams to resign as general counsel
Timothy Williams, Senior Vice President, General Counsel, and Secretary of Vanda Pharmaceuticals, is resigning, effective April 10, 2026, to pursue other opportunities. This leadership change occurs as Vanda Pharmaceuticals (NASDAQ:VNDA) shows strong stock performance, with shares up 57% over the past year, and appears undervalued despite burning cash towards expected profitability. The company recently received FDA approval for Bysanti and is navigating regulatory reviews for Hetlioz.
Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role
Vanda Pharmaceuticals announced that Timothy Williams, Senior Vice President, General Counsel, and Secretary, will resign from his position effective April 10, 2026. He notified the company on March 29, 2026, stating his intention to pursue other endeavors. This change was reported in an 8-K filing on April 2, 2026.
Timothy Williams resigns as Senior Vice President, General Counsel and Secretary at Vanda
Timothy Williams, the Senior Vice President, General Counsel, and Secretary at Vanda Pharmaceuticals Inc. (VNDA), has resigned from his position. His resignation is effective April 10, 2026, as he plans to pursue other endeavors. The company has not yet disclosed information regarding his replacement.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Update
Vanda Pharmaceuticals (NASDAQ:VNDA) experienced a significant 26.4% decrease in short interest by mid-March, with 3.2 million shares sold short, representing about 5.9% of its float. Despite this, the company has a "Moderate Buy" consensus from analysts with an average price target of $14.90, though insiders have recently sold a substantial amount of shares. Vanda Pharmaceuticals also missed its quarterly EPS and revenue estimates, reporting a negative net margin.
VNDA Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Vanda Pharmaceuticals Inc. (VNDA). It highlights a "Strong Sell" consensus based on various technical indicators, including moving averages and oscillators. The analysis details key support and resistance levels, momentum indicators like RSI and MACD, and how VNDA is performing relative to its moving averages.
Vanguard disaggregates holdings; reports 0 shares of Vanda Pharmaceuticals (VNDA)
Vanguard Group has filed an Amendment No. 7 to its Schedule 13G/A, stating it beneficially owns 0 shares (0%) of Vanda Pharmaceuticals Inc. common stock. This change is due to an internal realignment of Vanguard subsidiaries, where certain subsidiaries will now report their holdings separately, as permitted by SEC Release No. 34-39538. The filing indicates that the aggregate ownership for The Vanguard Group has been removed for this issuer, and separate 13G/13D entries from Vanguard affiliates should be expected.
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving Average - Here's Why
Vanda Pharmaceuticals (NASDAQ:VNDA) saw its share price move above its 200-day moving average, trading as high as $7.27, representing a roughly 6.3% intraday rise. Despite this technical breakout, the company missed its last quarterly EPS estimates and has negative margins and return on equity. While insiders have recently sold shares, institutional ownership remains high with several funds increasing their positions, and analysts hold a "Moderate Buy" consensus with an average price target of $14.90.
Vanda Pharmaceuticals stock faces institutional dominance amid biotech sector volatility and retail investor retreat
Vanda Pharmaceuticals (NASDAQ: VNDA), a biotech company focusing on neurology and rare diseases, is heavily influenced by institutional investors who own 88.14% of its shares. This dominance, coupled with a retreat of retail investors from US equities and a lack of recent major pipeline catalysts, makes the stock's trajectory dependent on broader market dynamics and insider control. The article highlights the risks and opportunities for US investors in small-cap biotechs with high institutional ownership and discusses Vanda's pipeline, which includes approved products and late-stage assets for CNS disorders and rare diseases.
Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) experienced a significant stock decline of 17.63% due to notable management uncertainties and investment challenges. The company faces a negative outlook driven by weak profitability, declining revenue, a substantial share sale by the CEO, and a negative regulatory ruling from the European Medicines Agency for its antipsychotic drug. Technical analysis suggests a bearish sentiment, recommending shorting the stock if it continues to fail at maintaining upward momentum.
If You Invested $1,000 in Vanda Pharma (VNDA)
This article analyzes the historical performance of a hypothetical $1,000 investment in Vanda Pharma (VNDA) over various periods, showing returns of +47.7% in one year, but significant losses over five and ten years, underperforming the S&P 500. It also provides detailed information about Vanda Pharma, Inc.'s focus on developing therapies for unmet medical needs in neurologic, psychiatric, and dermatologic conditions, highlighting its commercialized products and robust pipeline. The company's regulatory engagements with the FDA regarding products like HETLIOZ and NEREUS are also discussed.
Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks
Vanda Pharmaceuticals (VNDA) stock is down significantly due to disappointing clinical trial results for its antipsychotic iloperidone, which was refused marketing authorization in Europe. The company is also facing market speculation after its CEO offloaded a substantial number of shares. Financial analysis reveals operational losses despite a strong gross margin, pointing to liquidity issues and a bearish trend for the stock.
VNDA Financials: Revenue Breakdown, Margins & Competitor Comparison
The article analyzes Vanda Pharmaceuticals Inc. (VNDA) financials, detailing its revenue streams, profitability, and competitor comparisons. Fanapt is the primary revenue driver, contributing 55.5% of total sales. VNDA exhibits a high gross margin but negative operating and net margins, indicating challenges in converting revenue to profit.
Vanda Pharmaceuticals Faces Setbacks as CEO Mihael Polymeropoulos Sells Shares
Vanda Pharmaceuticals (VNDA) is facing significant challenges, with its stock trading down by 9.57%. This decline is attributed to CEO Mihael Polymeropoulos selling a large block of shares and the European medicines agency rejecting Vanda's iloperidone drug for schizophrenia and bipolar disorders. The company also reported a challenging financial overview, including negative operating income and limited cash reserves, leading to investor uncertainty.
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
Vanda Pharmaceuticals is urging the FDA to revise its new draft guidance on New Approach Methodologies (NAMs) to genuinely accelerate the shift from animal testing to human-relevant methods. While supporting the FDA's commitment to improving drug development ethics, Vanda finds the guidance lacks concrete examples, scientific references, and clear pathways for NAM validation. The company calls for a stronger, evidence-based approach to ensure faster access to safer drugs and reduce animal suffering.
Vanda Pharmaceuticals urges FDA to accelerate move away from animal testing
Vanda Pharmaceuticals is urging the U.S. Food and Drug Administration (FDA) to expedite the shift from traditional animal testing to more human-relevant methodologies. The company advocates for alternative approaches that leverage modern, human-based methods in drug development. This move aims to enhance the effectiveness and ethical standards of drug testing, aligning with a growing industry and public desire for advanced testing strategies that improve safety assessments and reduce reliance on animal models.
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
Vanda Pharmaceuticals (Nasdaq: VNDA) has expressed significant concerns regarding the FDA's new draft guidance on New Approach Methodologies (NAMs), which aims to reduce reliance on animal testing in drug development. While supporting the FDA's goal to improve human predictivity, Vanda argues the draft guidance lacks practical examples, clear benchmarks, and streamlined approval pathways needed to effectively transition from animal testing to human-relevant methods. Vanda urges the FDA to revise the draft to include stronger scientific grounding, concrete examples of accepted NAMs, and expedited regulatory acceptance pathways.
Vanda says FDA’s animal-testing overhaul lacks examples and speed
Vanda Pharmaceuticals has criticized the FDA's new draft guidance on New Approach Methodologies (NAMs), stating it lacks concrete examples, validation criteria, and clear pathways to replace animal testing. The company urges the FDA to withdraw and revise the guidance to incorporate robust scientific grounding, specific validated NAM examples, and expedited acceptance pathways. Vanda emphasizes its readiness to collaborate with the FDA and other stakeholders to advance regulatory policies that prioritize human-relevant science and reduce animal suffering.
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
Vanda Pharmaceuticals criticizes the FDA's new draft guidance on "New Approach Methodologies" (NAMs) for drug development, arguing it lacks concrete examples and clear pathways for replacing animal testing. While supporting the shift to human-relevant methods, Vanda calls for a substantial revision of the guidance to incorporate robust scientific grounding, specific validated NAMs, and expedited regulatory acceptance to accelerate safer drug development and reduce animal suffering.
Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag
Vanda Pharmaceuticals (VNDA) stock rose 17.4% after the FDA granted a rare formal evidentiary public hearing for its HETLIOZ jet lag disorder application. This hearing is significant as it challenges the FDA's proposed refusal of approval following a prior court ruling that criticized the agency's handling of Vanda's clinical evidence for HETLIOZ. While the hearing adds regulatory uncertainty, it also presents a potential opportunity for Vanda to expand HETLIOZ into a large, untreated market, complementing the recent approval of BYSANTI for bipolar I and schizophrenia.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of "Moderate Buy" from Analysts
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $14.90, despite missing recent quarterly earnings and revenue expectations. Insiders have been net sellers, offloading over 300,000 shares in the past three months, though institutional ownership remains high at around 88%. The company trades at approximately $8.81 with a market cap of $521 million and is focused on therapies for CNS disorders and rare diseases.
Vanda Pharmaceuticals Stock (ISIN: US92178N1054) Faces Heightened Scrutiny Amid Pipeline Setbacks an
Vanda Pharmaceuticals (VNDA) is experiencing stock pressure due to pipeline setbacks, particularly a missed primary endpoint in a key gastroparesis trial, and ongoing concerns about cash burn. Despite a relatively stable financial position with cash runway into 2027, the lack of immediate positive catalysts and slow revenue growth are causing caution among investors. European funds are monitoring the regulatory environment and comparing Vanda's risk-reward profile to that of other biotech firms, emphasizing the impact of rising US interest rates and the company's reliance on its existing niche products.
Vanda Pharmaceuticals Hits New 52-Week High of $9.94, Surges 59.87%
Vanda Pharmaceuticals, Inc. reached a new 52-week high of $9.94 on March 10, 2026, marking a significant increase from its $3.81 low and representing a 59.87% surge. The company, operating in the Pharmaceuticals & Biotechnology sector with a $340 million market cap, has outperformed the S&P 500 despite facing financial challenges, including negative return on equity. This achievement highlights its market position and performance relative to industry trends.
Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid
Vanda Pharmaceuticals' stock rose 13.3% after the FDA granted a rare formal evidentiary public hearing to review its application for HETLIOZ as a jet lag treatment. This decision follows a legal win against the FDA, emphasizing high scrutiny for expanding HETLIOZ's use. The outcome of this hearing, along with the recent approval of BYSANTI for bipolar I and schizophrenia, will significantly influence Vanda's risk profile and growth trajectory.
Vanda Pharmaceuticals (NASDAQ:VNDA) Sets New 52-Week High - What's Next?
Vanda Pharmaceuticals (NASDAQ:VNDA) recently hit a new 52-week high of $9.66 on heavy trading volume, despite mixed analyst ratings and an earnings miss. The company has an average "Moderate Buy" rating and a target price of $14.90, though insiders, including the CEO, have significantly sold shares. The biopharmaceutical company focuses on CNS disorders and rare diseases, with Hetlioz as its flagship product.
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline
Truist Securities has initiated coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a buy rating and an $18.00 price target, citing the company's diversified portfolio of three commercial drugs generating over $200 million in sales and several near-commercial-ready assets. The firm highlighted the recent FDA approval of Bysanti for schizophrenia and bipolar disorder and NEREUS as an adjunct therapy for GLP-1 induced vomiting, viewing NEREUS as a potential $1 billion opportunity. Despite some recent financial misses, InvestingPro analysis suggests the stock is undervalued and analysts predict profitability this year.
Truist Securities Initiates Coverage on Vanda Pharmaceuticals (VNDA) with Buy Rating | VNDA Stock News
Truist Securities has initiated coverage on Vanda Pharmaceuticals (VNDA) with a "Buy" rating and a price target of $18.00. This new coverage adds to existing analyst ratings, with the average analyst target price for VNDA being $14.88, suggesting an 81.40% upside from its current price. However, GuruFocus' estimated GF Value of $6.66 suggests a potential downside for the stock.
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline
Truist Securities initiated coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a buy rating and an $18 price target, citing the company's diversified portfolio of three commercial drugs and several near-commercial assets. Vanda recently received FDA approval for BYSANTI for schizophrenia and bipolar disorder and NEREUS for GLP-1 induced vomiting, the latter seen as a $1 billion opportunity. Despite a recent Q4 2025 earnings and revenue miss, analysts predict the company will turn profitable this year, and H.C. Wainwright also raised its price target to $24 following the Bysanti approval.
Truist Securities Initiates Coverage on Vanda Pharmaceuticals (VNDA) with Buy Rating
Truist Securities has initiated coverage on Vanda Pharmaceuticals (VNDA) with a "Buy" rating, setting a price target of USD 18.00. This new coverage adds to several recent analyst updates, including HC Wainwright & Co. maintaining "Buy" ratings with increased price targets and Jefferies and B. Riley Securities also raising their price targets. The average one-year target price from four analysts is $14.88, implying an 81.40% upside from its current price, and the consensus brokerage recommendation indicates an "Outperform" status.
Kevin Patrick Moran Sells 42,442 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock
Vanda Pharmaceuticals CFO Kevin Patrick Moran sold 42,442 shares of VNDA stock on March 2nd at an average price of $8.27, reducing his stake by 9.35%. This sale, along with other executive sales, occurred shortly after the company reported a Q4 EPS and revenue miss and maintained a negative net margin. Despite a "Hold" consensus rating from analysts with a target of $14.13, some firms have higher price targets.
Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target
Truist Financial initiated coverage on Vanda Pharmaceuticals (VNDA) with a "Buy" rating and set a price target of $18. The biopharmaceutical company recently had an insider sell shares worth over $1.2 million, and the FDA granted a landmark hearing for its drug HETLIOZ in jet lag disorder. Vanda Pharmaceuticals has a consensus analyst opinion of "Buy" with an average target price of $15.50.
Gunther Birznieks Sells 42,431 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock
Gunther Birznieks, SVP of Vanda Pharmaceuticals (NASDAQ:VNDA), sold 42,431 shares for over $350,000, reducing his stake by 7.91%. This sale was part of a larger executive selling trend, which included the CEO, CFO, and CMO, raising potential concerns for investors despite possible non-market reasons. The company continues to face challenges, having missed Q4 earnings and revenue estimates, though its stock is currently trading above key moving averages.
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) CEO Sells 156,235 Shares of Stock
Vanda Pharmaceuticals CEO Mihael Hristos Polymeropoulos sold 156,235 shares of VNDA stock for over $1.27 million, reducing his stake by 5.46%, with other senior executives also making significant sales. This comes as the FDA granted a formal evidentiary public hearing for Vanda's sNDA for Hetlioz in jet lag disorder, a rare step that could impact approval. Despite the insider selling, which can be viewed negatively, the stock traded up 4.6% to $8.20 and has a consensus target price of $14.13, although the company remains loss-making.
Vanda Pharmaceuticals (VNDA) SVP sells 42,431 shares to cover RSU tax
Gunther Birznieks, SVP of Business Development at Vanda Pharmaceuticals (VNDA), sold 42,431 shares of common stock on March 2, 2026, at a weighted average price of $8.2659 per share. These sales were made to cover tax obligations stemming from the settlement of vested Restricted Stock Units (RSUs). Following this transaction, Birznieks directly holds 494,197 shares of VNDA.
VNDA SEC Filings - Vanda Pharma 10-K, 10-Q, 8-K Forms
This article provides access to Vanda Pharma's (VNDA) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), and material events (8-K). It details recent company activities such as drug sales, pipeline updates, FDA interactions, and insider trading information. The platform also offers AI-powered summaries to help investors understand the key points of these regulatory documents.
[144] Vanda Pharmaceuticals Inc. SEC Filing
Vanda Pharmaceuticals Inc. has filed a Form 144 Notice of Proposed Sale of Securities with the SEC. The filing details the proposed sale of 30,800 shares of common stock by an individual, acquired through the vesting/settlement of Restricted Stock Units on March 1, 2026. The aggregate market value of these securities is reported as $254,589, to be sold on NASDAQ through Merrill Lynch.
VNDA Earnings History & Surprises | EPS & Revenue Results | VANDA PHARMACEUTICALS INC (NASDAQ:VNDA)
This article provides a detailed earnings history and surprise analysis for VANDA PHARMACEUTICALS INC (NASDAQ:VNDA), including past quarterly EPS and revenue results against analyst estimates. It highlights that VNDA has beaten EPS estimates in 3 out of the last 4 quarters, with an average beat of 8.9%, but has generally missed revenue estimates. The next earnings release is projected for May 5, 2026.
[144] Vanda Pharmaceuticals Inc. SEC Filing
This SEC filing (Form 144) for Vanda Pharmaceuticals Inc. (VNDA) details a proposed sale of securities, specifically 156,235 shares of Common Stock acquired through the vesting and settlement of Restricted Stock Units. The transaction occurred on March 1, 2026, with an approximate sale date of March 2, 2026, through Merrill Lynch on NASDAQ. The filing also provides recent news and other SEC filings for Vanda Pharmaceuticals.
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections
Vanda Pharmaceuticals is seeking approval for Hetlioz to treat jet lag disorder after multiple FDA rejections. The FDA has now granted Vanda a formal evidentiary public hearing to review the proposed refusal, a step the company notes has not been seen in drug approvals for over 40 years. This comes after legal intervention in 2025 that criticized the FDA's handling of Vanda's evidence.
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
Vanda Pharmaceuticals announced that the FDA has granted a formal evidentiary public hearing to review the proposed refusal of its supplemental new drug application (sNDA) for HETLIOZ® in jet lag disorder. This is a rare procedural step, marking the first such drug approval hearing in over 40 years, and follows a U.S. Court of Appeals ruling that criticized the FDA's handling of Vanda's previous application. Vanda believes this decision represents a significant step towards greater transparency from the FDA.
FDA grants first drug approval hearing in 40 years over jet lag pill
Vanda Pharmaceuticals announced that the FDA has granted a formal evidentiary public hearing to review the proposed refusal of its supplemental new drug application (sNDA) for HETLIOZ® in treating jet lag disorder. This is a rare and significant regulatory step, being the first such drug approval hearing in over 40 years, following a D.C. Circuit ruling that criticized the FDA's prior inadequate engagement with Vanda's evidence. While HETLIOZ® is currently approved for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome, Vanda is seeking to expand its approval for jet lag disorder, a condition lacking an FDA-approved therapeutic.
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
Vanda Pharmaceuticals announced that the FDA has granted its request for a formal evidentiary public hearing regarding the proposed refusal to approve HETLIOZ® for jet lag disorder. This marks a significant regulatory event, being the first such drug approval hearing in over 40 years, highlighting the complex legal and scientific issues involved. The decision follows a U.S. Court of Appeals ruling that criticized the FDA's earlier handling of Vanda's application.
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
Vanda Pharmaceuticals announced that the FDA has granted a formal evidentiary public hearing to review the proposed refusal of HETLIOZ® for jet lag disorder, marking the first such drug approval hearing in over 40 years. This decision follows a D.C. Circuit Court ruling that criticized the FDA's handling of Vanda's sNDA, which included statistically significant clinical trial results. HETLIOZ® is currently approved for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome, and its expanded approval for jet lag would address a significant unmet medical need.
Vanda Pharmaceuticals Inc. SEC Filing
This article reports on a Form 144 SEC filing by Vanda Pharmaceuticals Inc. (VNDA). The filing details the proposed sale of common stock acquired through the vesting/settlement of restricted stock units. The document includes information on the issuer, the securities to be sold, and confirms no adverse information regarding the company has been withheld.
[Form 4] Vanda Pharmaceuticals Inc. Insider Trading Activity
Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals Inc. (VNDA), reported a sale of 42,442 shares of common stock on March 2, 2026, to cover tax obligations related to vested RSU agreements. The shares were sold at a weighted average price of $8.2659, with transactions ranging from $8.085 to $8.81 per share. Following the sale, Moran directly owned 411,380 shares and indirectly owned an additional 635 shares.
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
Vanda Pharmaceuticals Inc. announced its participation in the 2026 Citizens Life Sciences Conference in Miami, scheduled for March 11, 2026. A corporate presentation will be held at 2:15 p.m. Eastern Time, accessible live on Vanda's corporate website. The company is a global biopharmaceutical firm focused on developing therapies for unmet medical needs.
[144] Vanda Pharmaceuticals Inc. SEC Filing
This article reports on a Form 144 SEC filing by Vanda Pharmaceuticals Inc. (VNDA). The filing, dated March 2, 2026, concerns the proposed sale of common stock acquired through the vesting and settlement of restricted stock units. The document details the filer and issuer information, the securities to be sold, and confirms no previous sales within the last three months.
